Brind.

FDA issued a Complete Response Letter to Disc Medicine, while Rosen Law Firm investigated securities claims for shareholders.

1 report, 1 independent Updated Jun 24

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA

Keep exploring

The entities involved

FDA
- Dario Amodei warns government leaders about AI risks and calls for strict guardrails on AI development.13:44
- Cognition Therapeutics, Inc. discussed registrational program key aspects with the FDA in May and received Notice of Allowance for a patent application on June 16.12:36

Related events

FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.Jun 11
The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.Jun 7

Coverage

Newest first; wire copies grouped

Jun 24prnewswire.com